Next Article in Journal
Failure Patterns and Morphological Soil–Rock Interface Characteristics of Frozen Soil–Rock Mixtures under Compression and Tension
Next Article in Special Issue
The Less Known Cyclins—Uncovered
Previous Article in Journal
Analytical Models for Fast and Accurate Calculation of Electromagnetic Performances of Segmented Permanent Magnet Synchronous Machines with Large Angular Gaps

Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells

Department of Proteomics, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820 Prague, Czech Republic
Author to whom correspondence should be addressed.
Appl. Sci. 2021, 11(1), 460;
Received: 24 November 2020 / Revised: 30 December 2020 / Accepted: 2 January 2021 / Published: 5 January 2021
Survivin is a 16.5 kDa protein highly expressed in centrosomes, where it controls proper sister chromatid separation. In addition to its function in mitosis, survivin is also involved in apoptosis. Overexpression of survivin in many cancer types makes it a suitable target for cancer therapy. Western blotting and confocal microscopy were used to characterize the effect of chemotherapy on acute myeloid leukemia (AML) cells. We found enhanced survivin expression in a panel of AML cell lines treated with cytarabine (Ara-C), which is part of a first-line induction regimen for AML therapy. Simultaneously, Ara-C caused growth arrest and depletion of the mitotic cell fraction. Subsequently, the effect of a second component of standard therapy protocol, idarubicin, and of a known survivin inhibitor, YM-155, on cell viability and survivin expression and localization in AML cells was investigated. Idarubicin reversed Ara-C-induced survivin upregulation in the majority of AML cell lines. YM-155 caused survivin deregulation together with a viability decrease in cells resistant to idarubicin treatment, suggesting that YM-155 might be efficient in a specific subset of AML patients. Expression levels of other apoptosis-related proteins, in particular X-linked inhibitor of apoptosis (XIAP), Mcl-1, and p53, and of the cell-cycle inhibitor p21 considerably changed in almost all cases, confirming the off-target effects of YM-155. View Full-Text
Keywords: survivin; cytarabine; idarubicin; YM-155; acute myeloid leukemia survivin; cytarabine; idarubicin; YM-155; acute myeloid leukemia
Show Figures

Figure 1

MDPI and ACS Style

Otevřelová, P.; Brodská, B. Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells. Appl. Sci. 2021, 11, 460.

AMA Style

Otevřelová P, Brodská B. Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells. Applied Sciences. 2021; 11(1):460.

Chicago/Turabian Style

Otevřelová, Petra; Brodská, Barbora. 2021. "Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells" Appl. Sci. 11, no. 1: 460.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop